28464907|t|Nodal skip metastasis in thoracic esophageal squamous cell carcinoma: a cohort study
28464907|a|Nodal skip metastasis is a prognostic factor in some sites of malignancies, but its role in esophageal cancer is still unclear. The present study aimed to investigate occurrence and effect of nodal skip metastases in thoracic esophageal squamous cell carcinoma. All 578 patients undergoing esophagectomy for thoracic esophageal squamous cell carcinoma at the Center for Esophageal Diseases located in Padova between January 1992 and December 2010 were retrospectively evaluated. Selection criteria were R0 resection, pathological M0 stage and pathological lymph node involvement. Patients receiving neoadjuvant therapy were excluded. The selection identified 88 patients with lymph node involvement confirmed by pathological evaluation. Sixteen patients (18.2%) had nodal skip metastasis. Adjusting for the number of lymph node metastases, patient with nodal skip metastasis had similar 5-year overall survival (14% vs. 13%, p = 0.93) and 5-year disease free survival (14% vs. 9%, p = 0.48) compared to patients with both peritumoral and distant lymph node metastases. The risk difference of nodal skip metastasis was: -24.1% (95% C.I. -43.1% to -5.2%) in patients with more than one lymph node metastasis compared to those with one lymph node metastasis; -2.3% (95% C.I. -29.8% to 25.2%) in middle thoracic esophagus and -23.0% (95% C.I. -47.8% to 1.8%) in lower thoracic esophagus compared to upper thoracic esophagus; 18.1% (95% C.I. 3.2% to 33.0%) in clinical N0 stage vs. clinical N+ stage. Nodal skip metastasis is a common pattern of metastatic lymph involvement in thoracic esophageal squamous cell carcinoma. However, neither overall survival nor disease free survival are associated with nodal skip metastasis occurrence.
28464907	0	5	Nodal	T082	C0443268
28464907	6	10	skip	T033	C0560435
28464907	11	21	metastasis	T191	C0596869
28464907	25	68	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	72	84	cohort study	T081	C0009247
28464907	85	90	Nodal	T082	C0443268
28464907	91	95	skip	T033	C0560435
28464907	96	106	metastasis	T191	C0596869
28464907	112	129	prognostic factor	T201	C1514474
28464907	147	159	malignancies	T191	C4282132
28464907	177	194	esophageal cancer	T191	C0014859
28464907	204	211	unclear	T033	C3845108
28464907	240	251	investigate	T169	C1292732
28464907	267	273	effect	T080	C1280500
28464907	277	282	nodal	T082	C0443268
28464907	283	287	skip	T033	C0560435
28464907	302	345	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	355	363	patients	T101	C0030705
28464907	375	388	esophagectomy	T061	C0085198
28464907	393	436	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	444	474	Center for Esophageal Diseases	T093	C1708333
28464907	486	492	Padova	UnknownType	C0681784
28464907	501	508	January	T080	C3829466
28464907	518	526	December	T080	C3830550
28464907	537	562	retrospectively evaluated	T062	C0035363
28464907	564	582	Selection criteria	T080	C0242801
28464907	588	600	R0 resection	T033	C0677874
28464907	602	614	pathological	T169	C1521733
28464907	615	623	M0 stage	T033	C0445034
28464907	628	640	pathological	T169	C1521733
28464907	641	663	lymph node involvement	T033	C0806692
28464907	665	673	Patients	T101	C1516213
28464907	684	703	neoadjuvant therapy	T061	C0600558
28464907	747	755	patients	T101	C0030705
28464907	761	783	lymph node involvement	T033	C0806692
28464907	797	809	pathological	T169	C1521733
28464907	810	820	evaluation	T058	C0220825
28464907	830	838	patients	T101	C1516213
28464907	851	856	nodal	T082	C0443268
28464907	857	861	skip	T033	C0560435
28464907	862	872	metastasis	T191	C0596869
28464907	902	923	lymph node metastases	T191	C0596869
28464907	925	932	patient	T101	C1516213
28464907	938	943	nodal	T082	C0443268
28464907	944	948	skip	T033	C0560435
28464907	949	959	metastasis	T191	C0596869
28464907	979	995	overall survival	T081	C4086681
28464907	1031	1052	disease free survival	T081	C0242793
28464907	1088	1096	patients	T101	C0030705
28464907	1107	1118	peritumoral	T082	C3897941
28464907	1123	1130	distant	T082	C0443203
28464907	1131	1152	lymph node metastases	T191	C0596869
28464907	1177	1182	nodal	T082	C0443268
28464907	1183	1187	skip	T033	C0560435
28464907	1188	1198	metastasis	T191	C0596869
28464907	1216	1219	C.I	T081	C0009667
28464907	1241	1249	patients	T101	C0030705
28464907	1269	1290	lymph node metastasis	T191	C0596869
28464907	1318	1339	lymph node metastasis	T191	C0596869
28464907	1352	1355	C.I	T081	C0009667
28464907	1377	1383	middle	T082	C0444598
28464907	1384	1402	thoracic esophagus	T023	C0227188
28464907	1419	1422	C.I	T081	C0009667
28464907	1443	1448	lower	T082	C0441994
28464907	1449	1467	thoracic esophagus	T023	C0227188
28464907	1480	1485	upper	T082	C1282910
28464907	1486	1504	thoracic esophagus	T023	C0227188
28464907	1517	1521	C.I.	T081	C0009667
28464907	1540	1548	clinical	T080	C0205210
28464907	1549	1557	N0 stage	T033	C0441959
28464907	1562	1570	clinical	T080	C0205210
28464907	1571	1579	N+ stage	T033	C1272457
28464907	1581	1586	Nodal	T082	C0443268
28464907	1587	1591	skip	T033	C0560435
28464907	1592	1602	metastasis	T191	C0596869
28464907	1626	1654	metastatic lymph involvement	T033	C0806692
28464907	1658	1701	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	1712	1719	neither	T080	C4284892
28464907	1720	1736	overall survival	T081	C4086681
28464907	1741	1762	disease free survival	T081	C0242793
28464907	1767	1782	associated with	T080	C0332281
28464907	1783	1788	nodal	T082	C0443268
28464907	1789	1793	skip	T033	C0560435
28464907	1794	1804	metastasis	T191	C0596869